Financial Reports Latest Updates Industry Maps Economic Calendar

Fortress Biotech, Inc. (FBIO) Annual Reports

Q: Where can I read Fortress Biotech, Inc. (FBIO) annual reports?

Every year on this page links straight to the full text on SEC EDGAR. US annual reports are web pages (HTML) rather than PDFs, so you can read and search them in the browser. 3 filings are currently indexed.

Q: What is the difference between a 10-K and a 20-F?

A 10-K is the annual report of a US domestic issuer; a 20-F is filed by foreign private issuers (Taiwanese companies with US ADRs, such as TSMC, file 20-F). A 40-F applies to Canadian issuers under the MJDS.

Fortress Biotech, Inc. is listed on Nasdaq, classified by the SEC under Pharmaceutical Preparations (SIC 2834). This page indexes 3 annual reports, each linking to the full text on the SEC's EDGAR system.

Company profile

Exchange： Nasdaq
Fiscal year end： 12/31
SEC CIK： 1429260 →

Website：Official site ↗

Financial Highlights

FY2026 Q2 (quarterly, ended 2026-06-30)
	Current	Prior year	YoY
Revenue	$18.7M	$16.4M	+14.0%
Operating income	$-10.0M	$-36.5M	+72.6%
Net income	$-468,000	$15.5M	-103.0%
EPS (diluted)	$-0.08	$0.45	-117.8%

Source: SEC EDGAR (XBRL company facts)

Financial history

Revenue & profit

Quarterly · In mn (USD)

Revenue 18.7 mn Net income -0.47 mn

Show table：Income statement

Item	2009Q4	2010Q3	2010Q4	2011Q2	2011Q3	2011Q4	2011Q4	2012Q4	2012Q4	2012Q4	2012Q4	2013Q4	2013Q4	2013Q4	2013Q4	2014Q4	2014Q2	2014Q3	2014Q4	2015Q1	2015Q2	2015Q3	2015Q4	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
Revenue	—	—	—	—	—	—	—	—	—	—	—	—	—	—	0	0	0	0	0	0.5	0	0.03	0.34	0.66	2.23	0.98	14.4	44.7	50.7	46.9	7.54	55.4	63.8	63.7	8.99	6.48	9.25	9.77	11.1	12.9	9.46	9.48	13.8	11.6	17.8	21.1	18.3	23.9	18.9	16.5	16.4	12.4	17.4	34.8	19.9	13.0	14.9	14.6	15.1	13.1	16.4	17.6	16.1	16.0	18.7
Gross profit	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	0	0.03	—	—	1.91	0.93	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Operating income	-2.61	-2.08	-2.39	-22.5	-3.74	-3.53	-5.23	-6.58	-6.46	-5.83	-8.23	-8.46	-10.3	-7.50	-9.52	-6.58	-4.76	-4.35	-4.96	-12.1	-7.76	-18.1	-13.0	-15.1	-15.1	-16.3	-32.2	-17.6	-23.2	-32.6	-73.2	-35.5	-24.6	-24.9	-41.2	-32.6	-25.3	-22.5	-30.4	-21.5	-25.4	-23.0	-24.3	-30.0	-42.9	-49.9	-62.0	-47.3	-50.9	-50.7	-54.6	-58.9	-50.1	-13.8	-19.6	-36.6	-27.8	-22.1	-23.8	-22.3	-36.5	-6.81	-4.79	-7.74	-10.0
Net income	-3.67	-2.12	-1.63	-22.5	-3.73	-3.36	-6.72	-6.56	-6.45	-5.93	-8.66	-8.86	-10.7	-7.83	-9.80	-7.37	-4.71	-4.59	-3.71	-12.1	-6.17	-18.2	-12.0	-12.2	-12.5	-13.0	-17.4	-12.0	-17.4	-27.1	-10.4	-21.0	-21.6	-16.6	-24.9	1.39	-13.1	-12.8	-15.5	-12.4	-13.3	-15.6	-5.29	-8.82	-3.53	-20.8	-31.6	-15.8	-21.4	-22.5	-26.9	-21.5	-24.8	-5.04	-9.28	-15.4	-10.9	-12.9	-6.76	-10.6	15.5	5.85	-3.94	110	-0.47

Balance sheet

Quarterly · In mn (USD)

Total assets 317 mn Total liabilities 111 mn

Equity = assets − liabilities. Balance-sheet figures are period-end balances, not cumulative.

Show table：Balance sheet

Item	2009Q4	2010Q3	2010Q4	2011Q2	2011Q3	2011Q4	2011Q4	2012Q4	2012Q4	2012Q4	2012Q4	2013Q4	2013Q4	2013Q4	2013Q4	2014Q4	2014Q2	2014Q3	2014Q4	2015Q1	2015Q2	2015Q3	2015Q4	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
Current assets	—	—	14.9	—	—	26.8	23.4	18.0	38.5	48.0	40.6	45.1	68.1	107	100	80.5	76.5	72.1	70.5	69.6	62.0	66.6	99.8	84.3	76.5	98.6	110	152	190	184	183	200	172	160	111	137	164	166	156	159	200	238	262	318	320	301	346	341	299	258	230	202	128	97.8	117	117	103	86.3	90.4	127	110	119	124	295	246
Total assets	—	—	14.9	—	—	26.8	23.4	18.0	38.5	48.1	41.0	45.5	68.8	107	101	94.9	90.9	88.0	89.3	90.5	83.7	86.9	119	105	98.1	145	171	212	250	245	246	265	237	225	141	201	227	222	226	229	269	296	329	391	418	408	397	408	364	324	294	264	181	151	168	165	146	127	144	178	160	181	186	357	317
Current liabilities	—	—	1.56	—	—	3.69	3.49	3.84	3.93	4.47	5.13	6.17	8.95	9.64	11.2	4.34	3.44	3.56	4.08	5.93	5.00	8.45	10.6	10.8	14.3	38.6	56.6	52.8	53.5	68.4	67.4	79.3	62.2	70.8	55.6	49.0	36.4	46.9	45.6	51.7	57.0	37.3	48.0	53.8	70.6	103	101	103	105	106	128	129	129	97.3	84.9	87.7	75.5	70.3	71.4	73.7	57.5	54.1	49.7	103	62.0
Total liabilities	—	—	1.56	—	—	4.44	4.24	4.59	4.68	19.0	19.0	18.7	20.2	19.6	19.3	19.4	18.5	18.8	18.8	30.3	28.5	31.9	34.3	34.0	39.9	70.6	87.8	85.6	99.2	124	125	158	141	140	121	150	137	147	154	153	152	120	132	147	170	195	171	214	216	222	244	244	197	164	166	169	160	140	146	146	123	116	123	155	111
Equity	-10.1	—	-15.9	—	—	-44.6	19.1	13.4	33.8	29.1	22.0	26.7	48.6	87.5	81.3	75.5	72.4	69.3	70.5	60.2	55.9	53.6	56.9	44.6	35.3	36.6	38.5	47.8	72.3	36.9	52.6	41.6	43.9	37.8	1.85	20.8	31.9	25.8	26.2	37.2	60.5	97.1	100	106	108	92.7	109	97.9	77.2	61.7	41.7	37.8	18.5	16.7	22.5	23.0	17.9	21.2	22.7	22.3	43.9	55.9	49.9	162	164

Cash flow

Quarterly · In mn (USD)

Operating -59.3 mn Investing -0.08 mn Financing 0.09 mn

Positive = cash in, negative = cash out.

Show table：Cash flow statement

Item	2009Q4	2010Q3	2010Q4	2011Q2	2011Q3	2011Q4	2011Q4	2012Q4	2012Q4	2012Q4	2012Q4	2013Q4	2013Q4	2013Q4	2013Q4	2014Q4	2014Q2	2014Q3	2014Q4	2015Q1	2015Q2	2015Q3	2015Q4	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
Operating	-2.35	-4.82	-0.86	-1.78	-2.57	-2.93	-3.66	-5.42	-6.01	-4.66	-7.10	-7.49	-62.4	-7.22	-7.13	-6.07	-4.01	-2.72	-3.53	-8.83	-7.87	-6.54	2.86	-11.6	-7.38	-8.82	-18.0	-11.5	-23.9	-26.1	-23.9	-27.6	-27.7	-22.5	-21.0	-25.3	-28.3	-16.3	-25.1	-21.9	-17.4	-23.9	-20.5	-21.7	-34.5	-21.7	-38.7	-46.9	-41.4	-43.3	-47.8	-43.2	-33.3	-16.8	-34.9	-25.4	-21.8	-20.1	-12.9	-19.6	-27.6	-6.11	-12.5	204	-59.3
Investing	0	0	-0.01	-3.81	-0.03	0	0	0	-3.88	0	-0.28	0	-4.43	0.08	0	-0.25	-0.29	-0.05	-22.7	-1.36	-0.05	-20.0	29.3	-2.70	-4.22	2.17	-1.30	-0.94	-20.2	-24.8	4.37	-1.97	-2.29	9.32	13.8	24.1	-0.61	-3.75	0.31	-1.78	-1.06	-2.76	-1.57	-0.46	-4.84	-7.54	53.4	-21.3	-0.31	-0.89	-0.39	-5.00	-2.04	5.00	-0.06	0	0	0	-15.0	1.17	6.09	2.87	0	0	-0.08
Financing	3.86	19.1	-0.05	—	23.0	-0.01	0.11	0	26.5	13.9	0.11	11.3	135	45.5	0.39	-13.2	0.13	-1.44	4.37	9.36	0.03	11.1	40.5	-2.43	1.52	17.9	25.9	58.2	54.4	17.1	24.5	39.7	4.38	9.96	-3.35	52.1	61.9	5.55	27.2	22.8	65.8	46.8	37.0	78.7	24.4	6.97	38.9	50.0	2.99	3.75	18.6	22.2	-30.4	-2.68	43.6	27.9	14.3	2.71	25.8	52.1	4.52	15.1	5.71	-27.4	0.09
Cash at period end	1.51	15.8	14.9	9.27	29.6	26.7	23.2	17.7	38.2	47.5	40.2	44.0	67.9	106	99.5	80.0	75.8	71.6	49.8	48.9	41.0	25.6	98.2	81.4	71.3	82.5	88.3	134	144	111	114	124	98.6	95.9	65.5	116	149	135	137	136	183	218	233	290	275	253	306	288	249	208	178	152	78.0	72.3	80.9	83.8	76.2	58.9	57.3	91.3	74.4	86.2	79.4	256	197

Profitability

Quarterly · %

Gross margin 95.8% Operating margin -53.5% Net margin -2.5%

Gross, operating and net margin = the respective profit ÷ revenue.

Show table：Profitability

Item	2009Q4	2010Q3	2010Q4	2011Q2	2011Q3	2011Q4	2011Q4	2012Q4	2012Q4	2012Q4	2012Q4	2013Q4	2013Q4	2013Q4	2013Q4	2014Q4	2014Q2	2014Q3	2014Q4	2015Q1	2015Q2	2015Q3	2015Q4	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
Gross margin	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	100.0%	—	—	85.5%	95.8%	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Operating margin	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	-2414.2%	—	-72288.0%	-3835.5%	-2286.5%	-678.7%	-1666.3%	-223.7%	-39.3%	-45.8%	-69.5%	-969.8%	-64.0%	-38.5%	-39.1%	-458.4%	-503.4%	-273.4%	-230.7%	-273.0%	-166.7%	-268.5%	-243.2%	-176.8%	-259.1%	-240.2%	-236.8%	-339.3%	-197.6%	-269.6%	-307.0%	-333.1%	-473.6%	-288.2%	-39.6%	-98.3%	-280.6%	-186.6%	-151.0%	-157.6%	-169.8%	-222.2%	-38.6%	-29.8%	-48.3%	-53.5%
Net margin	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	-2411.2%	—	-72644.0%	-3560.9%	-1849.2%	-559.5%	-1331.4%	-121.0%	-26.8%	-34.3%	-57.8%	-138.1%	-37.9%	-33.9%	-26.1%	-276.7%	21.5%	-141.6%	-130.6%	-139.2%	-95.8%	-140.8%	-164.1%	-38.5%	-76.1%	-19.8%	-98.6%	-172.7%	-65.9%	-113.1%	-136.2%	-164.3%	-173.3%	-142.5%	-14.5%	-46.5%	-118.3%	-73.5%	-88.0%	-44.7%	-80.5%	94.3%	33.2%	-24.5%	688.2%	-2.5%

Returns & leverage

Quarterly · %

ROE 107.5% ROA 46.9% Debt ratio 34.9%

ROE / ROA = trailing four-quarter net income ÷ average equity / total assets (annual mode: the year’s net income ÷ average of opening and closing). Not computed when the denominator is zero or negative.

Show table：Returns & leverage

Item	2009Q4	2010Q3	2010Q4	2011Q2	2011Q3	2011Q4	2011Q4	2012Q4	2012Q4	2012Q4	2012Q4	2013Q4	2013Q4	2013Q4	2013Q4	2014Q4	2014Q2	2014Q3	2014Q4	2015Q1	2015Q2	2015Q3	2015Q4	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
ROE	—	—	—	—	—	—	-2247.9%	-151.5%	-68.3%	—	-134.1%	-148.9%	-82.9%	-61.8%	-71.9%	-69.8%	-49.1%	-33.8%	-26.9%	-37.0%	-41.4%	-65.3%	-76.0%	-92.8%	-120.3%	-110.2%	-115.6%	-118.9%	-111.1%	-200.9%	-146.9%	-169.8%	-138.0%	-186.5%	-309.2%	-197.7%	-140.4%	-155.3%	-284.8%	-185.1%	-116.8%	-92.3%	-73.5%	-60.0%	-39.4%	-40.5%	-61.9%	-70.3%	-96.5%	-118.2%	-115.1%	-136.2%	-200.1%	-199.9%	-188.7%	-179.3%	-223.7%	-256.4%	-203.2%	-181.8%	-47.7%	10.3%	18.8%	138.5%	107.5%
ROA	—	—	—	—	—	-116.7%	-189.8%	-112.9%	-60.0%	-68.5%	-85.8%	-94.2%	-63.6%	-46.4%	-52.5%	-50.8%	-37.2%	-27.1%	-21.5%	-27.1%	-30.4%	-45.9%	-46.6%	-49.7%	-60.4%	-42.8%	-38.1%	-34.6%	-34.4%	-37.8%	-32.1%	-31.8%	-32.9%	-29.6%	-43.5%	-26.5%	-22.9%	-22.1%	-21.8%	-25.0%	-21.8%	-21.9%	-16.8%	-13.9%	-9.7%	-10.9%	-17.8%	-17.9%	-22.9%	-24.9%	-25.1%	-27.5%	-35.2%	-33.0%	-26.3%	-25.5%	-24.9%	-35.0%	-29.5%	-24.0%	-9.6%	2.6%	4.1%	47.8%	46.9%
Debt ratio	—	—	10.4%	—	—	16.6%	18.1%	25.5%	12.2%	39.4%	46.3%	41.2%	29.4%	18.3%	19.2%	20.4%	20.4%	21.3%	21.1%	33.5%	34.0%	36.8%	28.9%	32.4%	40.6%	48.5%	51.4%	40.4%	39.7%	50.5%	51.0%	59.4%	59.4%	62.4%	86.0%	74.7%	60.5%	66.2%	68.0%	67.1%	56.5%	40.5%	40.1%	37.5%	40.6%	47.9%	43.0%	52.5%	59.4%	68.7%	83.0%	92.5%	108.8%	108.8%	99.0%	102.4%	110.0%	110.0%	101.1%	81.8%	76.6%	64.1%	66.5%	43.3%	34.9%

EPS

Quarterly · US$

EPS US$-0.08

Show table：EPS

Item	2009Q4	2010Q3	2010Q4	2011Q2	2011Q3	2011Q4	2011Q4	2012Q4	2012Q4	2012Q4	2012Q4	2013Q4	2013Q4	2013Q4	2013Q4	2014Q4	2014Q2	2014Q3	2014Q4	2015Q1	2015Q2	2015Q3	2015Q4	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
EPS（US$）	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	-0.49	—	—	—	0.02	—	—	—	-0.19	—	—	—	-0.11	-0.04	-0.26	-0.38	-0.18	-0.24	-0.25	-0.29	-0.21	-0.24	-0.94	-0.53	-1.04	-0.73	-0.76	-0.26	-0.48	0.45	0.11	-0.21	2.82	-0.08

Revenue & profit

Year-to-date · In mn (USD)

Revenue 34.8 mn Net income 110 mn

Year-to-date = summed from the first quarter of the fiscal year; balance-sheet items are period-end balances.

Balance sheet

Year-to-date · In mn (USD)

Total assets 317 mn Total liabilities 111 mn

Equity = assets − liabilities. Balance-sheet figures are period-end balances, not cumulative.

Cash flow

Year-to-date · In mn (USD)

Operating 145 mn Investing -0.08 mn Financing -27.3 mn

Positive = cash in, negative = cash out.

Profitability

Year-to-date · %

Operating margin -51.1% Net margin 316.2%

Gross, operating and net margin = the respective profit ÷ revenue.

Returns & leverage

Year-to-date · %

ROE 107.5% ROA 46.9% Debt ratio 34.9%

EPS

Year-to-date · US$

EPS US$2.74

Revenue & profit

Annual · In mn (USD)

Revenue 63.3 mn Net income 6.82 mn

Annual = sum of four quarters of a complete fiscal year (incomplete years are omitted); balance-sheet items are year-end balances.

Show table：Income statement

Item	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Revenue	0.86	18.3	150	192	36.6	45.6	68.8	75.7	84.5	57.7	63.3
Operating income	-50.9	-78.7	-147	-126	-111	-94.3	-185	-204	-142	-110	-70.4
Net income	-48.4	-55.1	-66.9	-84.2	-40.0	-46.5	-64.7	-86.6	-60.6	-46.0	6.82

Balance sheet

Annual · In mn (USD)

Total assets 186 mn Total liabilities 123 mn

Equity = assets − liabilities. Balance-sheet figures are period-end balances, not cumulative.

Show table：Balance sheet

Item	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Current assets	99.8	110	183	111	156	262	346	230	117	90.4	124
Total assets	119	171	246	141	226	329	397	294	168	144	186
Current liabilities	10.6	56.6	67.4	55.6	45.6	48.0	101	128	84.9	71.4	49.7
Total liabilities	34.3	87.8	125	121	154	132	171	244	166	146	123
Equity	56.9	38.5	52.6	1.85	26.2	100	109	41.7	22.5	22.7	49.9

Cash flow

Annual · In mn (USD)

Operating -65.8 mn Investing 10.1 mn Financing 77.4 mn

Positive = cash in, negative = cash out.

Show table：Cash flow statement

Item	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Operating	-20.4	-45.8	-85.4	-98.8	-95.0	-83.7	-117	-179	-128	-80.2	-65.8
Investing	7.89	-6.06	-41.6	18.8	20.1	-7.16	40.5	-22.9	-2.10	-15.0	10.1
Financing	60.9	42.9	154	50.6	147	172	149	75.3	32.7	70.6	77.4
Cash at period end	98.2	88.3	114	65.5	137	233	306	178	80.9	57.3	79.4

Profitability

Annual · %

Operating margin -111.3% Net margin 10.8%

Gross, operating and net margin = the respective profit ÷ revenue.

Show table：Profitability

Item	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Operating margin	-5894.4%	-430.7%	-97.8%	-65.7%	-302.5%	-206.7%	-268.6%	-268.8%	-168.4%	-191.2%	-111.3%
Net margin	-5611.6%	-301.6%	-44.6%	-43.8%	-109.1%	-102.0%	-94.1%	-114.3%	-71.8%	-79.8%	10.8%

Returns & leverage

Annual · %

ROE 18.8% ROA 4.1% Debt ratio 66.5%

Show table：Returns & leverage

Item	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
ROE	-85.2%	-115.6%	-146.9%	-309.2%	-284.8%	-73.5%	-61.9%	-115.1%	-188.7%	-203.2%	18.8%
ROA	-40.8%	-38.1%	-32.1%	-43.5%	-21.8%	-16.8%	-17.8%	-25.1%	-26.3%	-29.5%	4.1%
Debt ratio	28.9%	51.4%	51.0%	86.0%	68.0%	40.1%	43.0%	83.0%	99.0%	101.1%	66.5%

EPS

Annual · US$

EPS US$-0.13

Show table：EPS

Item	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
EPS（US$）	—	—	—	—	—	—	-0.79	-0.96	-1.92	-2.79	-0.13

Source: SEC EDGAR (XBRL company facts)

Annual reports by year

	10-K
2025	Open full text →
2024	Open full text →
2023	Open full text →

10-K: annual report of a US domestic issuer. Filings are the original documents hosted on SEC EDGAR — this site neither mirrors nor edits them.

FAQ

Where can I read Fortress Biotech, Inc. (FBIO) annual reports?

Every year in the table above links straight to the full text on SEC EDGAR. US annual reports are web pages (HTML) rather than PDFs, so you can read and search them in the browser without downloading anything. 3 filings are currently indexed.

What is the difference between a 10-K and a 20-F?

A 10-K is the annual report of a US domestic issuer, with sections fixed by law: Item 1 Business, Item 1A Risk Factors, Item 7 Management's Discussion and Analysis. A 20-F is filed by foreign private issuers — Taiwanese companies with US ADRs, such as TSMC, file 20-F rather than 10-K. A 40-F applies to Canadian issuers under the MJDS.

Are earnings call materials available here?

No. Earnings calls are not SEC filings, so US pages on this site cover annual reports only. Taiwan has a mandatory investor-conference disclosure regime, and those materials are indexed under Annual Reports.

Source: US Securities and Exchange Commission (SEC) EDGAR. This site indexes public filings and links to them; it hosts no copies, offers no investment advice, and makes no warranty as to timeliness or completeness.
Back to US annual reports, or see the supply-chain maps.